$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-K Financial Statement

#000092706619000025 Filed on February 22, 2019

Income Statement

Concept	2018 Q4	2017 Q4	2017 Q3
Revenue	$2.821B	$2.781B	$2.765B
YoY Change	1.45%	3.02%	1.46%
Cost Of Revenue	$2.027B	$1.942B	$1.952B
YoY Change	4.4%	-473.84%	-27.65%
Gross Profit	$794.1M	$839.2M	$813.5M
YoY Change	-5.37%	324.91%	-21.24%
Gross Profit Margin	28.15%	30.18%	29.42%
Selling, General & Admin	$268.5M	$259.8M	$270.2M
YoY Change	3.35%	-346.02%	-34.21%
% of Gross Profit	33.81%	30.96%	33.21%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$155.1M	$184.0M	$203.3M
YoY Change	-15.71%	-2.54%	11.83%
% of Gross Profit	19.53%	21.93%	24.99%
Operating Expenses	$423.7M	$404.1M	$412.9M
YoY Change	4.85%	-416.94%	-30.3%
Operating Profit	$387.9M	$150.3M	$395.3M
YoY Change	158.03%	-58.64%	-51.38%
Interest Expense	-$138.9M	-$112.2M	-$114.6M
YoY Change	23.8%	21.96%	14.14%
% of Operating Profit	-35.81%	-74.63%	-28.99%
Other Income/Expense, Net	-$500.0K	$5.500M	$3.396M
YoY Change	-109.09%	-1016.67%	81.02%
Pretax Income	$259.1M	$46.83M	$289.4M
YoY Change	453.34%	-81.97%	-59.26%
Income Tax	$51.70M	$101.7M	$90.55M
% Of Pretax Income	19.95%	217.19%	31.29%
Net Earnings	-$149.8M	$303.4M	-$214.5M
YoY Change	-149.37%	92.36%	-137.54%
Net Earnings / Revenue	-5.31%	10.91%	-7.76%
Basic Earnings Per Share	-$0.90	$1.66	-$1.14
Diluted Earnings Per Share	-$0.90	$1.64	-$1.12
COMMON SHARES
Basic Shares Outstanding	166.0M shares	183.3M shares	188.9M shares
Diluted Shares Outstanding			191.4M shares

Balance Sheet

Concept	2018 Q4	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$361.4M	$578.8M	$1.104B
YoY Change	-37.56%	-42.8%	-31.65%
Cash & Equivalents	$323.0M	$508.2M	$846.1M
Short-Term Investments	$38.36M	$70.53M	$257.5M
Other Short-Term Assets	$5.594B	$112.1M	$205.2M
YoY Change	4892.06%	12.61%	15.94%
Inventory	$107.4M	$181.8M	$154.4M
Prepaid Expenses	$108.3M	$104.7M
Receivables	$1.859B	$1.715B	$2.091B
Other Receivables	$469.8M	$399.3M	$599.4M
Total Short-Term Assets	$8.424B	$8.771B	$4.034B
YoY Change	-3.95%	119.56%	-5.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.394B	$3.149B	$3.386B
YoY Change	7.76%	9.95%	11.2%
Goodwill	$6.842B	$6.610B	$9.416B
YoY Change	3.5%	9.89%	0.35%
Intangibles	$118.8M	$113.8M	$1.451B
YoY Change	4.41%	54.86%	-7.94%
Long-Term Investments	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Assets	$71.58M	$47.29M	$61.64M
YoY Change	51.38%	39.67%	43.41%
Total Long-Term Assets	$10.69B	$10.20B	$14.98B
YoY Change	4.73%	-30.87%	2.15%
TOTAL ASSETS
Total Short-Term Assets	$8.424B	$8.771B	$4.034B
Total Long-Term Assets	$10.69B	$10.20B	$14.98B
Total Assets	$19.11B	$18.97B	$19.01B
YoY Change	0.72%	1.17%	0.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$463.3M	$509.1M	$566.9M
YoY Change	-9.01%	11.5%	13.74%
Accrued Expenses	$659.0M	$616.0M	$775.0M
YoY Change	6.98%	-36.95%	-8.39%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.929B	$178.0M	$190.0M
YoY Change	983.71%	11.25%	24.18%
Total Short-Term Liabilities	$4.891B	$3.068B	$2.875B
YoY Change	59.45%	13.15%	8.92%
LONG-TERM LIABILITIES
Long-Term Debt	$8.173B	$9.158B	$8.909B
YoY Change	-10.76%	2.38%	-0.7%
Other Long-Term Liabilities	$450.7M	$365.3M	$548.2M
YoY Change	23.36%	15.11%	30.24%
Total Long-Term Liabilities	$450.7M	$365.3M	$548.2M
YoY Change	23.36%	15.11%	30.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.891B	$3.068B	$2.875B
Total Long-Term Liabilities	$450.7M	$365.3M	$548.2M
Total Liabilities	$14.08B	$13.08B	$13.02B
YoY Change	7.65%	1.12%	1.42%
SHAREHOLDERS EQUITY
Retained Earnings	$2.743B	$3.634B	$4.071B
YoY Change	-24.51%	-2.06%	-19.86%
Common Stock	$995.2M	$1.043B	$1.059B
YoY Change	-4.59%	1.53%	2.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00	$0.00	$348.8M
YoY Change			-69.62%
Treasury Stock Shares
Shareholders Equity	$3.703B	$4.690B	$4.785B
YoY Change
Total Liabilities & Shareholders Equity	$19.11B	$18.97B	$19.01B
YoY Change	0.72%	1.17%	0.46%

Cashflow Statement

Concept	2018 Q4	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$149.8M	$303.4M	-$214.5M
YoY Change	-149.37%	92.36%	-137.54%
Depreciation, Depletion And Amortization	$155.1M	$184.0M	$203.3M
YoY Change	-15.71%	-2.54%	11.83%
Cash From Operating Activities	$419.1M	$480.7M	$503.2M
YoY Change	-12.81%	-5.11%	-6.07%
INVESTING ACTIVITIES
Capital Expenditures	-$281.4M	-$265.5M	$240.9M
YoY Change	5.99%	4.57%	11.21%
Acquisitions
YoY Change
Other Investing Activities	-$62.80M	$6.200M	-$13.00M
YoY Change	-1112.9%	-98.0%	-95.4%
Cash From Investing Activities	-$344.3M	-$259.2M	-$253.9M
YoY Change	32.83%	-567.03%	-49.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-202.1M	-236.5M	-164.6M
YoY Change	-14.55%	-56.53%	-59.3%
NET CHANGE
Cash From Operating Activities	419.1M	480.7M	503.2M
Cash From Investing Activities	-344.3M	-259.2M	-253.9M
Cash From Financing Activities	-202.1M	-236.5M	-164.6M
Net Change In Cash	-127.3M	-15.00M	84.70M
YoY Change	748.67%	-182.87%	-123.04%
FREE CASH FLOW
Cash From Operating Activities	$419.1M	$480.7M	$503.2M
Capital Expenditures	-$281.4M	-$265.5M	$240.9M
Free Cash Flow	$700.5M	$746.2M	$262.3M
YoY Change	-6.12%	-1.88%	-17.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	166400000	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	11900000000	USD
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2018	dei	Trading Symbol TradingSymbol	DVA
CY2018	dva	Percentage Change In Discount Rate Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInDiscountRateUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.0100
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	182462278	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166387307	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	182462278	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166387307	shares
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Registrant Name EntityRegistrantName	DAVITA INC.
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10709981000	USD
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10093670000	USD
CY2016	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9727360000	USD
CY2018	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	49587000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	485364000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	431304000	USD
CY2018	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	10660394000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9608306000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9296056000	USD
CY2018	us-gaap	Other Income OtherIncome	744457000	USD
CY2017	us-gaap	Other Income OtherIncome	1268328000	USD
CY2016	us-gaap	Other Income OtherIncome	1411411000	USD
CY2018	us-gaap	Revenues Revenues	11404851000	USD
CY2017	us-gaap	Revenues Revenues	10876634000	USD
CY2016	us-gaap	Revenues Revenues	10707467000	USD
CY2018	dva	Patient Care Costs PatientCareCosts	8195513000	USD
CY2017	dva	Patient Care Costs PatientCareCosts	7640005000	USD
CY2016	dva	Patient Care Costs PatientCareCosts	7431582000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1135454000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1064026000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1072841000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	591035000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	559911000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	509497000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-7300000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-7033000	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	11677000	USD
CY2018	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4484000	USD
CY2017	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-8640000	USD
CY2016	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	16874000	USD
CY2018	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	17338000	USD
CY2017	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	295234000	USD
CY2016	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	14993000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3106000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	36196000	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	28415000	USD
CY2018	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	60603000	USD
CY2017	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	6273000	USD
CY2016	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	374374000	USD
CY2018	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2017	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	526827000	USD
CY2016	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	9879027000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	9063879000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	8677757000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	1525824000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	1812755000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	2029710000	USD
CY2018	us-gaap	Interest And Debt Expense InterestAndDebtExpense	487435000	USD
CY2017	us-gaap	Interest And Debt Expense InterestAndDebtExpense	430634000	USD
CY2016	us-gaap	Interest And Debt Expense InterestAndDebtExpense	414116000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10089000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17665000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7511000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1048478000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1399786000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1623105000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	258400000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323859000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	431761000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	790078000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1075927000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1191344000	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-457038000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-245372000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-158262000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	173646000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	166937000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	153208000	USD
CY2018	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	159394000	USD
CY2017	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	663618000	USD
CY2016	us-gaap	Net Income Loss Including Portion Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest	879874000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.66
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.78
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.12
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.93
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.52
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.36
CY2018	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.62
CY2017	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.71
CY2016	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.04
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.47
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.29
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	170785999	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188625559	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	201641173	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	172364581	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	191348533	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204904656	shares
CY2018	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	624321000	USD
CY2017	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	901277000	USD
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1032373000	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-464927000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-237659000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-152499000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	159394000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	663618000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	879874000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-133000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-3670000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-5437000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1858608000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-6286000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-5058000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-2566000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3705000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1427000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	220000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	423000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-45944000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	99770000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-39614000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax	-10087000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-39791000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	102876000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-29627000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	293249000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	933431000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1003455000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	173646000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	166935000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	153398000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	119603000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	766496000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	850057000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	323038000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	508234000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92382000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10686000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2935000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	32830000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1714750000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	107381000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	181799000	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	469796000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	399262000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	111840000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	595850000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	579005000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	658913000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	112058000	USD
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	68614000	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	49440000	USD
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5389565000	USD
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5761642000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	8424159000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	8770701000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3393669000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3149213000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118846000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	113827000	USD
CY2018Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	224611000	USD
CY2017Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	245534000	USD
CY2018Q4	us-gaap	Long Term Investments LongTermInvestments	35424000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	37695000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	71583000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	47287000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	6841960000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	6610279000	USD
CY2018Q4	us-gaap	Assets Assets	19110252000	USD
CY2017Q4	us-gaap	Assets Assets	18974536000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	463270000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	509116000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	616116000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1929369000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	178213000	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1243759000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1185070000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4891161000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3067520000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8172847000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9158018000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	450669000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	365325000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	562536000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	486247000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	14077213000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	196037000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3908398000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4886066000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19110252000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18974536000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2018	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	591035000	USD
CY2017	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	777485000	USD
CY2016	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	720252000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	35092000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	38338000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	273660000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-395217000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	13077110000	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1124641000	USD
CY2017Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1011360000	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	166000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	182000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	995006000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1042899000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2743194000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3633713000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-34924000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	13235000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	3703442000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4690029000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	204956000	USD
CY2018	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	61981000	USD
CY2017	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	981589000	USD
CY2016	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	296408000	USD
CY2018	dva	Disposal Group Including Discontinued Operations Valuation Adjustment DisposalGroupIncludingDiscontinuedOperationsValuationAdjustment	316840000	USD
CY2017	dva	Disposal Group Including Discontinued Operations Valuation Adjustment DisposalGroupIncludingDiscontinuedOperationsValuationAdjustment	0	USD
CY2016	dva	Disposal Group Including Discontinued Operations Valuation Adjustment DisposalGroupIncludingDiscontinuedOperationsValuationAdjustment	0	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	73061000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	52010000	USD
CY2018	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-26449000	USD
CY2017	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-28925000	USD
CY2016	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-17766000	USD
CY2018	dva	Net Gain Loss On Disposition Of Business Interests NetGainLossOnDispositionOfBusinessInterests	85699000	USD
CY2017	dva	Net Gain Loss On Disposition Of Business Interests NetGainLossOnDispositionOfBusinessInterests	23402000	USD
CY2016	dva	Net Gain Loss On Disposition Of Business Interests NetGainLossOnDispositionOfBusinessInterests	404165000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-82374000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-66920000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	7343000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	81176000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	156305000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	152240000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-73505000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	18625000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22920000	USD
CY2018	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-236995000	USD
CY2017	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	111432000	USD
CY2016	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	45351000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3497000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	11945000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-35893000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-35959000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	26876000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	11897000	USD
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	84165000	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-78239000	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	68272000	USD
CY2018	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-157462000	USD
CY2017	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1908000	USD
CY2016	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	176494000	USD
CY2018	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-23635000	USD
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-52176000	USD
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	77376000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1031000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	11157000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	30517000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1771640000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1913166000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1972126000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	987138000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	905250000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	829095000	USD
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	183156000	USD
CY2017	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	803879000	USD
CY2016	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	563856000	USD
CY2018	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	150205000	USD
CY2017	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	92336000	USD
CY2016	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	64725000	USD
CY2018	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8448000	USD
CY2017	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	13117000	USD
CY2016	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	13539000	USD
CY2018	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	5963000	USD
CY2017	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	228990000	USD
CY2016	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1133192000	USD
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	9526000	USD
CY2017	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	6408000	USD
CY2016	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	18963000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	34862000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	492470000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	1240502000	USD
CY2018	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	19177000	USD
CY2017	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	4816000	USD
CY2016	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	27096000	USD
CY2018	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2017	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2016	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	40920000	USD
CY2018	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	3646000	USD
CY2017	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	106000	USD
CY2016	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1005643000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1364732000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1201668000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	59934750000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50991960000	USD
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	51991490000	USD
CY2018	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	59239973000	USD
CY2017	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	50837112000	USD
CY2016	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	52116120000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1161511000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	802949000	USD
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1097822000	USD
CY2018	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	196441000	USD
CY2017	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	211467000	USD
CY2016	us-gaap	Payments Of Distributions To Affiliates PaymentsOfDistributionsToAffiliates	192401000	USD
CY2018	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	13577000	USD
CY2017	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	21252000	USD
CY2016	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	23543000	USD
CY2018	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2017	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	13251000	USD
CY2018	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	52311000	USD
CY2017	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	74552000	USD
CY2016	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	47590000	USD
CY2018	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	15000	USD
CY2017	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2864000	USD
CY2016	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2018	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	28082000	USD
CY2017	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5357000	USD
CY2016	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	21512000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-625354000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-766257000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1351981000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-3350000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	254000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4276000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137293000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-217569000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-577247000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	518920000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	683463000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1244917000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	415420000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	518920000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	683463000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2018	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates<div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. Although actual results in subsequent periods will differ from these estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time. All significant assumptions and estimates underlying the amounts reported in the financial statements and accompanying notes are regularly reviewed and updated when necessary. Changes in estimates are reflected in the financial statements based upon on-going actual experience trends, or subsequent settlements and realizations depending on the nature and predictability of the estimates and contingencies. Interim changes in estimates related to annual operating costs are applied prospectively within annual periods.</span></div>The most significant assumptions and estimates underlying these financial statements and accompanying notes involve revenue recognition and accounts receivable, contingencies, impairments of goodwill and investments, accounting for income taxes, consolidation of variable interest entities, and certain fair value estimates. Specific estimating risks and contingencies are further addressed within these notes to the consolidated financial statements.
CY2018Q4	dva	Number Of Entities That Third Parties Held Non Controlling Equity Interests NumberOfEntitiesThatThirdPartiesHeldNonControllingEquityInterests	653	entity
CY2018	us-gaap	Revenues Revenues	11404851000	USD
CY2017	us-gaap	Revenues Revenues	10876634000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	485364000	USD
CY2016	us-gaap	Revenues Revenues	10707467000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	431304000	USD
CY2018	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	624321000	USD
CY2017	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	901277000	USD
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1032373000	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-464927000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-237659000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-152499000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	159394000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	663618000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	879874000	USD
CY2018	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	171886000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	190820000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	203835000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	1100000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	170786000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188626000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	201641000	shares
CY2018	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	3.66
CY2017	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	4.78
CY2016	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	5.12
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.73
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.26
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.76
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.93
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.52
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.36
CY2018	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	171886000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	190820000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	203835000	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	479000	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	529000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1070000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	172365000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	191349000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204905000	shares
CY2018	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	3.62
CY2017	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	4.71
CY2016	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	5.04
CY2018	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-2.70
CY2017	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.24
CY2016	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.75
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.92
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.47
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.29
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5295000	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4350000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2523000	shares
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92382000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10686000	USD
CY2018Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	79329000	USD
CY2018Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	2235000	USD
CY2018Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	36124000	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	38359000	USD
CY2017Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	31630000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38895000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	70525000	USD
CY2018Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	2235000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2935000	USD
CY2017Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	31630000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	1200000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	32830000	USD
CY2018Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	35424000	USD
CY2017Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	37695000	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	37695000	USD
CY2018Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	2235000	USD
CY2018Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	36124000	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	38359000	USD
CY2017Q4	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	31630000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	38895000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	70525000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	360000	USD
CY2017	dva	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Sold In Current Quarter Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfSoldInCurrentQuarterNetOfTax	220000	USD
CY2018Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	469796000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	399262000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	108315000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	104727000	USD
CY2018Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	3525000	USD
CY2017Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	7331000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	111840000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	112058000	USD
CY2018Q4	us-gaap	Land Land	37384000	USD
CY2017Q4	us-gaap	Land Land	33814000	USD
CY2018Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	467181000	USD
CY2017Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	473489000	USD
CY2018Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	3164943000	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2816675000	USD
CY2018Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2586564000	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2352246000	USD
CY2018Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	661695000	USD
CY2017Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	576651000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6917767000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6252875000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3524098000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3103662000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3393669000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3149213000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	574799000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	544129000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	494945000	USD
CY2018	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	25978000	USD
CY2017	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	19176000	USD
CY2016	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	12990000	USD
CY2018	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	296000	USD
CY2017	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	203000	USD
CY2016	dva	Amortization Of Intangible Assets And Liabilities Net AmortizationOfIntangibleAssetsAndLiabilitiesNet	232000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	131360000	USD
CY2017Q4	us-gaap	Finite Lived Noncompete Agreements Gross FiniteLivedNoncompeteAgreementsGross	429140000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Asset Off Market Lease Favorable Gross FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross	7584000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Asset Off Market Lease Favorable Gross FiniteLivedIntangibleAssetOffMarketLeaseFavorableGross	7623000	USD
CY2018Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	59885000	USD
CY2017Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	33255000	USD
CY2018Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	583000	USD
CY2017Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	583000	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	199412000	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	470601000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	80566000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	356774000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118846000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	113827000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	16236000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15782000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14552000	USD
CY2018Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	5930000	USD
CY2017Q4	us-gaap	Off Market Lease Unfavorable OffMarketLeaseUnfavorable	5447000	USD
CY2018Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	4362000	USD
CY2017Q4	dva	Intangible Lease Liabilities Accumulated Amortization IntangibleLeaseLiabilitiesAccumulatedAmortization	3508000	USD
CY2018	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-28064000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	6841960000	USD
CY2018Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	224611000	USD
CY2017Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	245534000	USD
CY2018Q3	us-gaap	Equity Method Investment Additional Information EquityMethodInvestmentAdditionalInformation	During the third quarter of 2018, the investors in the APAC JV jointly agreed to a six-month deferral of the subscribed incremental capital contributions originally scheduled for August 1, 2018 based upon revised assessments of the capital needs of the joint venture.
CY2018Q4	dva	Number Of Partnerships NumberOfPartnerships	22
CY2018Q4	us-gaap	Cost Method Investments Aggregate Carrying Amount Not Evaluated For Impairment CostMethodInvestmentsAggregateCarryingAmountNotEvaluatedForImpairment	12386000	USD
CY2018	dva	Valuation Adjustment ValuationAdjustment	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	6015375000	USD
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	617032000	USD
CY2017	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	32386000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	36196000	USD
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	46454000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	6610279000	USD
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	278348000	USD
CY2018	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	15497000	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3106000	USD
CY2018Q4	us-gaap	Goodwill Gross GoodwillGross	6869233000	USD
CY2018Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	27273000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	6841960000	USD
CY2018	dva	Percentage Change In Operating Income Used To Evaluate Fair Value Of Reporting Unit For Goodwill Assessment PercentageChangeInOperatingIncomeUsedToEvaluateFairValueOfReportingUnitForGoodwillAssessment	0.03
CY2018Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	302244000	USD
CY2017Q4	us-gaap	Customer Advances And Deposits Current CustomerAdvancesAndDepositsCurrent	292370000	USD
CY2018Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	58569000	USD
CY2017Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	64924000	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	82827000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	83362000	USD
CY2018Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	28663000	USD
CY2017Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	28317000	USD
CY2018Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	123547000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	110032000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	595850000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	579005000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1083578000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1725822000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1278754000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-35100000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-326036000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	344351000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1048478000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1399786000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1623105000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	88412000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	21096000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	37347000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-28530000	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4659000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	140064000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	330191000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	322940000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	32990000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	47228000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	44525000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	7557000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3422000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1928000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	180611000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	380841000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	369393000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	52034000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-98760000	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	4431000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	2486000	USD
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	77789000	USD
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-56982000	USD
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	62368000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	258400000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323859000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	431761000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	258400000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323859000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	431761000	USD
CY2018	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	99768000	USD
CY2017	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	-364856000	USD
CY2016	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Discontinued Operation During Phase Out Period DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod	24052000	USD
CY2018	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	358168000	USD
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	-40997000	USD
CY2016	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	455813000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026
CY2018	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	0
CY2017	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	-0.002
CY2016	dva	Effective Income Tax Rate Reconciliation Gain On Changes In Ownership Interest EffectiveIncomeTaxRateReconciliationGainOnChangesInOwnershipInterest	-0.099
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.023
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2018	dva	Effective Income Tax Reconciliation Investment Impairment EffectiveIncomeTaxReconciliationInvestmentImpairment	0
CY2017	dva	Effective Income Tax Reconciliation Investment Impairment EffectiveIncomeTaxReconciliationInvestmentImpairment	0.064
CY2016	dva	Effective Income Tax Reconciliation Investment Impairment EffectiveIncomeTaxReconciliationInvestmentImpairment	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.205
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.019
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	70474000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	61282000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	61529000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	30934000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	23762000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	772118000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.018
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.046
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.033
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.029
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.246
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.231
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.266
CY2018Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	19327000	USD
CY2017Q4	dva	Deferred Tax Assets Receivables DeferredTaxAssetsReceivables	19705000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	106506000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	96537000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	117511000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	108429000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	36712000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	37794000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	280056000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	262465000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	209582000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	201183000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	555822000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	501763000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	118008000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	100376000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	67354000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	687430000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	562536000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	486247000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9192000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32776000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	24066000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6111000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7606000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	4134000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	804000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	338000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1380000	USD
CY2018	dva	Unrecognized Tax Benefits Increase Resulting From Tax Cuts And Jobs Act Of2017 UnrecognizedTaxBenefitsIncreaseResultingFromTaxCutsAndJobsActOf2017	0	USD
CY2017	dva	Unrecognized Tax Benefits Increase Resulting From Tax Cuts And Jobs Act Of2017 UnrecognizedTaxBenefitsIncreaseResultingFromTaxCutsAndJobsActOf2017	3731000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	2301000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	2051000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	40382000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32776000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	40382000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	37538000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	7606000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32776000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	9019000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	4195000	USD
CY2018Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10154216000	USD
CY2017Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	9400182000	USD
CY2018Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	52000000	USD
CY2017Q4	dva	Discount And Deferred Finance Costs DiscountAndDeferredFinanceCosts	63951000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	10102216000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	9336231000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1929369000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	178213000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	8172847000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	9158018000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	1929369000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	80016000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	3314149000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1291472000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	37881000	USD
CY2018Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3501329000	USD
CY2018	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0496
CY2018Q4	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0519
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	461897000	USD
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	406341000	USD
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	394013000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	25538000	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	24293000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	20103000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	483488000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	36754000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	462154000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	41044000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	432950000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	34026000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	395462000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	33690000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	349649000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	33845000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	1589949000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	194611000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3713652000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	373970000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	91233000	USD
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	282737000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	596117000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	530748000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	478531000	USD
CY2018Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	235194000	USD
CY2017Q4	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	257772000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2018	us-gaap	Defined Benefit Plan Benefit Obligation Benefits Paid DefinedBenefitPlanBenefitObligationBenefitsPaid	67807000	USD
CY2018	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	Contingencies<div style="line-height:120%;padding-bottom:12px;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in a highly regulated industry and is a party to various lawsuits, claims, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> suits, governmental investigations and audits (including investigations resulting from its obligation to self-report suspected violations of law) and other legal proceedings. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company’s total recorded accruals, including DMG, with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company’s best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.</span></div><div style="line-height:120%;padding-top:13px;text-indent:37px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.</span></div><div style="line-height:120%;padding-top:13px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inquiries by the Federal Government and Certain Related Civil Proceedings</span></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2016 U.S. Attorney Texas Investigation</span><span style="font-family:inherit;font-size:10pt;">: In early February 2016, the Company announced that its pharmacy services’ wholly-owned subsidiary, DaVita Rx, LLC (DaVita Rx), received a Civil Investigative Demand (CID) from the U.S. Attorney’s Office, Northern District of Texas. The government is conducting a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company’s relationships with pharmaceutical manufacturers. The CID covers the period from January 1, 2006 through the present. In connection with the Company’s ongoing efforts working with the government, the Company learned that a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaint had been filed covering some of the issues in the CID and practices that had been identified by the Company in a self-disclosure filed with the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services (HHS) in February 2016. In December 2017, the Company finalized and executed a settlement agreement with the government and relators in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> matter that included total monetary consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$63,700</span></span><span style="font-family:inherit;font-size:10pt;">, as previously disclosed, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$41,500</span></span><span style="font-family:inherit;font-size:10pt;"> was an incremental cash payment and </span><span style="font-family:inherit;font-size:10pt;"><span>$22,200</span></span><span style="font-family:inherit;font-size:10pt;"> was for amounts previously refunded, and all of which was previously accrued. The government’s investigation into certain of the Company's relationships with pharmaceutical manufacturers is ongoing, and in July 2018 the OIG served the Company with a subpoena seeking additional documents and information relating to those relationships. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Massachusetts Investigation</span><span style="font-family:inherit;font-size:10pt;">: In January 2017, the Company was served with an administrative subpoena for records by the U.S. Attorney’s Office, District of Massachusetts, relating to an investigation into possible federal </span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">health care offenses. The subpoena covers the period from January 1, 2007 through the present, and seeks documents relevant to charitable patient assistance organizations, particularly the American Kidney Fund, including documents related to efforts to provide patients with information concerning the availability of charitable assistance. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Colorado Investigation</span><span style="font-family:inherit;font-size:10pt;">: In November 2017, the U.S. Attorney’s Office, District of Colorado informed the Company of an investigation it was conducting into possible federal health care offenses involving DaVita Kidney Care, as well as several of the Company’s wholly-owned subsidiaries, including DMG, DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In August 2018, the Company received a CID from the U.S. Attorney's Office. The CID was issued pursuant to the FCA and covers the period from January 2005 through the present. In connection with the resolution of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">2015 U.S. OIG Medicare Advantage Civil Investigation</span><span style="font-family:inherit;font-size:10pt;"> referred to below, the Company resolved possible claims relating to DMG in this investigation. The Company is continuing to cooperate with the government in this investigation. </span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2017 U.S. Attorney Florida Investigation</span><span style="font-family:inherit;font-size:10pt;">: In November 2017, the U.S. Attorney’s Office, Southern District of Florida informed the Company of an investigation it was conducting into possible federal healthcare offenses involving the Company's wholly-owned subsidiary, Lifeline. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2018 U.S. Attorney Florida Investigation</span><span style="font-family:inherit;font-size:10pt;">: In March 2018, DaVita Labs received two CIDs from the U.S. Attorney’s Office, Middle District of Florida that were identical in nature but directed to the two different labs. According to the face of the CIDs, the U.S. Attorney’s Office is conducting an investigation as to whether the Company’s subsidiary submitted claims for blood, urine, and fecal testing, where there were insufficient test validation or stability studies to ensure accurate results, in violation of the FCA. In October 2018, DaVita Labs received a subpoena from the OIG in connection with this matter requesting certain patient records linked to clinical laboratory tests. The Company is continuing to cooperate with the government in this investigation.</span></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">* * </span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators and to develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies and/or private civil </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam</span><span style="font-family:inherit;font-size:10pt;"> complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company’s reputation, required changes to the Company’s business practices, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, possible criminal penalties, any of which could have a material adverse effect on the Company.</span></div><div style="line-height:120%;padding-top:13px;text-indent:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shareholder and Derivative Claims</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Peace Officers’ Annuity and Benefit Fund of Georgia Securities Class Action Civil Suit</span><span style="font-family:inherit;font-size:10pt;">: On February 1, 2017, the Peace Officers’ Annuity and Benefit Fund of Georgia filed a putative federal securities class action complaint in the U.S. District Court for the District of Colorado against the Company and certain executives. The complaint covers the time period of August 2015 to October 2016 and alleges, generally, that the Company and its executives violated</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">federal securities laws concerning the Company’s financial results and revenue derived from patients who received charitable premium assistance from an industry-funded non-profit organization. The complaint further alleges that the process by which patients obtained commercial insurance and received charitable premium assistance was improper and "created a false impression of DaVita’s business and operational status and future growth prospects." In November 2017, the court appointed the lead plaintiff and an amended complaint was filed on January 12, 2018. On March 27, 2018, the Company and various individual defendants filed a motion to dismiss. Briefing on the motion is complete. The plaintiffs filed an opposition to the motion to dismiss on June 6, 2018. The Company filed a reply in support of the motion on July 19, 2018. The Company disputes these allegations and intends to defend this action accordingly.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">In re DaVita Inc. Stockholder Derivative Litigation</span><span style="font-family:inherit;font-size:10pt;">: On August 15, 2017, the U.S. District Court for the District of Delaware consolidated three previously disclosed shareholder derivative lawsuits: the Blackburn Shareholder action filed on February 10, 2017, the Gabilondo Shareholder action filed on May 30, 2017, and the City of Warren Police and Fire Retirement </span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">System Shareholder action filed on June 9, 2017. The complaint covers the time period from 2015 to present and alleges, generally, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and misrepresentations and/or failures to disclose certain information in violation of the federal securities laws in connection with an alleged practice to direct patients with government-subsidized health insurance into private health insurance plans to maximize the Company’s profits. An amended complaint was filed in September 2017, and on December 18, 2017, the Company filed a motion to dismiss and a motion to stay proceedings in the alternative. The plaintiffs filed an opposition to the motion to dismiss on March 9, 2018. On June 25, 2018, the U.S. District Court for the District of Delaware granted the Company’s motion to stay proceedings and stayed the case until January 7, 2019, the date of the next status conference. During the status conference on January 7, 2019 the court further extended the stay until February 8, 2019. The parties submitted a proposed scheduling order on that date. The Company asked the Court to rule on the fully-briefed motion to dismiss before opening discovery. The Company disputes these allegations and intends to defend this action accordingly.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;padding-left:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Proceedings</span></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the foregoing, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Resolved Matters</span></div><div style="line-height:120%;padding-top:13px;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2011 Suit against the U.S. Department of Veterans Affairs</span><span style="font-family:inherit;font-size:10pt;">: As previously disclosed, the Company had a pending lawsuit in the U.S. Court of Federal Claims against the federal government which was originally filed in May 2011. The lawsuit related to the U.S. Department of Veterans Affairs (VA) underpayment of dialysis services the Company provided from 2005 through 2011 to veterans pursuant to VA regulations. In the first quarter of 2017, the Company received a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$538,000</span></span><span style="font-family:inherit;font-size:10pt;"> related to the settlement with the VA. The Company's consolidated entities recognized a net gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$527,000</span></span><span style="font-family:inherit;font-size:10pt;"> on this settlement. The Company's nonconsolidated and managed entities recognized a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$9,000</span></span><span style="font-family:inherit;font-size:10pt;">, of which the Company's equity investment share was </span><span style="font-family:inherit;font-size:10pt;"><span>$3,000</span></span><span style="font-family:inherit;font-size:10pt;">. The net effect was a net increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$530,000</span></span><span style="font-family:inherit;font-size:10pt;"> to the Company's operating income.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2015 OIG Medicare Advantage Civil Investigation</span><span style="font-family:inherit;font-size:10pt;">: In March 2015, JSA HealthCare Corporation (JSA), a subsidiary of DMG, received a subpoena from the OIG requesting documents and information for the period from January 1, 2008 through December 31, 2013, for certain MA plans for which JSA provided services. It also requested information regarding JSA’s communications about patient diagnoses as they related to certain MA plans generally, and more specifically as related to two Florida physicians with whom JSA previously contracted.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the subpoena described above, in June 2015, the Company received a civil subpoena from the OIG seeking production of a wide range of documents relating to the Company’s and its subsidiaries’ (including DMG and its subsidiary JSA) provision of services to MA plans and related patient diagnosis coding and risk adjustment submissions and payments. The Company believes that the request was part of a broader industry investigation into MA patient diagnosis coding and risk adjustment practices and potential overpayments by the government. The information requested included information related to patient diagnosis coding practices for a number of conditions, including potentially improper historical DMG coding for a particular condition. With respect to that condition, the guidance related to that coding issue was discontinued following the Company’s November 1, 2012, acquisition of HealthCare Partners (now known as the Company's DMG business), and the Company notified Centers for Medicare and Medicaid Services (CMS) in April 2015 of the coding practice and potential overpayments. In that regard, the Company identified certain additional coding practices which may have been problematic, some of which were the subject of the previously disclosed and dismissed</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Swoben Private Civil Suit</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company entered into a settlement agreement with the DOJ and OIG to resolve these matters on </span><span style="font-family:inherit;font-size:10pt;"><span>September 28, 2018</span></span><span style="font-family:inherit;font-size:10pt;">. As previously disclosed, an escrow established in connection with the Company's acquisition of HealthCare Partners in 2012 held back a portion of the purchase price to the prior owners of HealthCare Partners as security for the indemnification rights of the Company. The settlement amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$270,000</span></span><span style="font-family:inherit;font-size:10pt;"> was paid with these escrowed funds.</span></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">White, Kathleen, et al. v. DaVita Healthcare Partners, Inc., Civil Action No. 15-cv-2106, U.S. District Court for the District of Colorado</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:10pt;"><span>Three</span></span><span style="font-family:inherit;font-size:10pt;"> actions (Menchaca v. DaVita Healthcare Partners, Inc., Saldana v. DaVita Healthcare Partners, Inc. and Hardin v. DaVita Healthcare Partners, Inc.) were consolidated in December 2016 into one action in U.S. District Court for the District of Colorado. In all three actions, the plaintiffs brought claims for wrongful death based on allegations related to Granuflo®, a product used as a component of the dialysis process. The Menchaca and Saldana actions arose out of the treatment of patients in California, while the Hardin action arose out of the treatment of a patient in Illinois. On </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap">June 27, 2018</span></span></span><span style="font-family:inherit;font-size:10pt;">, </span></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the jury returned a verdict in favor of the plaintiffs, collectively awarding </span><span style="font-family:inherit;font-size:10pt;"><span>$8,500</span></span><span style="font-family:inherit;font-size:10pt;"> in compensatory damages and </span><span style="font-family:inherit;font-size:10pt;"><span>$375,000</span></span><span style="font-family:inherit;font-size:10pt;"> in punitive damages. Judgment on this verdict was not entered. In November 2018, the parties settled all three of the consolidated actions collectively for </span><span style="font-family:inherit;font-size:10pt;"><span>$25,500</span></span><span style="font-family:inherit;font-size:10pt;">, and all </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> cases were dismissed with prejudice. One of the Company’s insurance carriers paid </span><span style="font-family:inherit;font-size:10pt;"><span>$9,200</span></span><span style="font-family:inherit;font-size:10pt;"> of the settlement. The Company believes it is probable that it will be able to recover the remainder of the settlement amount from other insurers, indemnitors, and the like; however, the Company can make no assurances that it will recover the full amount.</span></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> * *</span></div><span style="font-family:inherit;font-size:10pt;">Other than as described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note </span><span style="font-family:inherit;font-size:10pt;">17</span> to these consolidated financial statements, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company’s revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management’s attention and result in significant legal expense, and may result in the diversion of significant operational resources, or otherwise harm the Company’s business, results of operations, financial condition, cash flows or reputation.
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	6162797	shares
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	69.90
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1422529	shares
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	73.39
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	31045000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	34895000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	73944000	USD
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	13473000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	28397000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2018	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	16844067	shares
CY2017	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	12966672	shares
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1153511000	USD
CY2017	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	810949000	USD
CY2018	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	68.48
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	95822000	USD
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend	0	USD
CY2018	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	85759000	USD
CY2017	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	61978000	USD
CY2016	dva	Longterm Incentive Program Compensation Cost LongtermIncentiveProgramCompensationCost	64956000	USD
CY2018	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	13591000	USD
CY2017	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	7717000	USD
CY2016	dva	Employee Service Share Based Compensation Estimated Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationEstimatedTaxBenefitFromCompensationExpense	12731000	USD
CY2018Q4	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Net LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedNet	99935000	USD
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	88596000	USD
CY2018	dva	Longterm Incentive Program Awards Compensation Cost Not Yet Recognized Period For Recognition LongtermIncentiveProgramAwardsCompensationCostNotYetRecognizedPeriodForRecognition	P0Y9M18D
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	14704000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	9727000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	7988000	USD
CY2017	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	62.54
CY2018Q3	dva	Stock Repurchase Program Additional Authorized Amount StockRepurchaseProgramAdditionalAuthorizedAmount	1389999000	USD
CY2017Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	110001000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11210000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	159394000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	663618000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	879874000	USD
CY2018	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	141576000	USD
CY2017	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	660752000	USD
CY2016	dva	Net Income Attributable To Parent Net Of Transfers To Noncontrolling Interests NetIncomeAttributableToParentNetOfTransfersToNoncontrollingInterests	866769000	USD
CY2018	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	28082000	USD
CY2017	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	5357000	USD
CY2016	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	21512000	USD
CY2018	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	28152000	USD
CY2018	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11508555000	USD
CY2017	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	11176736000	USD
CY2018	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	634326000	USD
CY2017	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	922718000	USD
CY2018	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	3.71
CY2017	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	4.89
CY2018	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	3.68
CY2017	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	4.82
CY2017Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	6388000	USD
CY2018	dva	Business Combination Contingent Consideration Acquisitions BusinessCombinationContingentConsiderationAcquisitions	1246000	USD
CY2018	dva	Business Combination Contingent Consideration Acquisitions Fair Value Remeasurement Gain Loss BusinessCombinationContingentConsiderationAcquisitionsFairValueRemeasurementGainLoss	4729000	USD
CY2018	dva	Business Combination Contingent Consideration Acquisitions Earnouts Payments BusinessCombinationContingentConsiderationAcquisitionsEarnoutsPayments	297000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	2608000	USD
CY2018	dva	Disposal Group Including Discontinued Operations Valuation Adjustment DisposalGroupIncludingDiscontinuedOperationsValuationAdjustment	316840000	USD
CY2017	dva	Disposal Group Including Discontinued Operations Valuation Adjustment DisposalGroupIncludingDiscontinuedOperationsValuationAdjustment	0	USD
CY2016	dva	Disposal Group Including Discontinued Operations Valuation Adjustment DisposalGroupIncludingDiscontinuedOperationsValuationAdjustment	0	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-457038000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-245372000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-158262000	USD
CY2018	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	290684000	USD
CY2017	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	357274000	USD
CY2016	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	287044000	USD
CY2018	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-57382000	USD
CY2017	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-232329000	USD
CY2016	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-430917000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	917922000	USD
CY2018Q4	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	507445000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2018	us-gaap	Revenues Revenues	11404851000	USD
CY2017	us-gaap	Revenues Revenues	10876634000	USD
CY2016	us-gaap	Revenues Revenues	10707467000	USD
CY2018	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	90108000	USD
CY2017	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	44966000	USD
CY2016	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	13628000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	1525824000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	1812755000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	2029710000	USD
CY2018	us-gaap	Interest And Debt Expense InterestAndDebtExpense	487435000	USD
CY2017	us-gaap	Interest And Debt Expense InterestAndDebtExpense	430634000	USD
CY2016	us-gaap	Interest And Debt Expense InterestAndDebtExpense	414116000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10089000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17665000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7511000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1048478000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1399786000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1623105000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	591035000	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	559911000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	509497000	USD
CY2018Q4	us-gaap	Assets Assets	19110252000	USD
CY2017Q4	us-gaap	Assets Assets	18974536000	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	48378000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	987138000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	905250000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	829095000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	92526000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	387159000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	339411000	USD
CY2018	us-gaap	Interest Paid InterestPaid	488974000	USD
CY2017	us-gaap	Interest Paid InterestPaid	424547000	USD
CY2016	us-gaap	Interest Paid InterestPaid	406987000	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	8828000	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	28127000	USD
CY2018Q4	us-gaap	Revenues Revenues	2821124000	USD
CY2018Q3	us-gaap	Revenues Revenues	2847330000	USD
CY2018Q2	us-gaap	Revenues Revenues	2886953000	USD
CY2018Q1	us-gaap	Revenues Revenues	2849444000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	387908000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	289038000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	438192000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	410686000	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	160332000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	73371000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	199603000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	191015000	USD
CY2018Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-310104000	USD
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-210167000	USD
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	67673000	USD
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-12329000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-149772000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-136796000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	267276000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	178686000	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.97
CY2018Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.44
CY2018Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.16
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.07
CY2018Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.87
CY2018Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.26
CY2018Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.40
CY2018Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.07
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.56
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.00
CY2018Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.96
CY2018Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.44
CY2018Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.15
CY2018Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.05
CY2018Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.86
CY2018Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.26
CY2018Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.38
CY2018Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.07
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.98
CY2017Q4	us-gaap	Revenues Revenues	2780913000	USD
CY2017Q3	us-gaap	Revenues Revenues	2765071000	USD
CY2017Q2	us-gaap	Revenues Revenues	2699399000	USD
CY2017Q1	us-gaap	Revenues Revenues	2631251000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	150337000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	395294000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	391196000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	875928000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	156210000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	152870000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	151292000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	440905000	USD
CY2017Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	147186000	USD
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-367346000	USD
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-24291000	USD
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	6792000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	303396000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-214476000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	127001000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	447697000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.86
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.81
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.79
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.29
CY2017Q4	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.80
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.95
CY2017Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.13
CY2017Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.66
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.66
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.33
CY2017Q4	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.85
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.80
CY2017Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.78
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	2.26
CY2017Q4	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.79
CY2017Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-1.92
CY2017Q2	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.13
CY2017Q1	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	0.03
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.64
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.12
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.65
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.29
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	173646000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	159394000	USD
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10093670000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	485364000	USD
CY2017	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9608306000	USD
CY2017	us-gaap	Other Income OtherIncome	1268328000	USD
CY2018Q4	us-gaap	Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain	28152000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	23470000	USD
CY2017Q3	us-gaap	Restructuring Charges RestructuringCharges	9569000	USD
CY2017Q3	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	11100000	USD
CY2017Q2	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	3600000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10709981000	USD
CY2018	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	49587000	USD
CY2018	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	10660394000	USD
CY2018	us-gaap	Other Income OtherIncome	744457000	USD
CY2018	us-gaap	Revenues Revenues	11404851000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	9879027000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	1525824000	USD
CY2018	us-gaap	Interest And Debt Expense InterestAndDebtExpense	487435000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10089000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	258400000	USD
CY2018	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	790078000	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-457038000	USD
CY2017	us-gaap	Revenues Revenues	10876634000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	9063879000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	1812755000	USD
CY2017	us-gaap	Interest And Debt Expense InterestAndDebtExpense	430634000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17665000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323859000	USD
CY2017	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2017	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1075927000	USD
CY2017	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-245372000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	166937000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	663618000	USD
CY2016	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	9727360000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	431304000	USD
CY2016	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9296056000	USD
CY2016	us-gaap	Other Income OtherIncome	1411411000	USD
CY2016	us-gaap	Revenues Revenues	10707467000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	8677757000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1858608000	USD
CY2018Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	760566000	USD
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5389565000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	8424159000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	2029710000	USD
CY2016	us-gaap	Interest And Debt Expense InterestAndDebtExpense	414116000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7511000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	431761000	USD
CY2016	dva	Equity In Earnings Loss Of Consolidated Affiliates EquityInEarningsLossOfConsolidatedAffiliates	0	USD
CY2016	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	1191344000	USD
CY2016	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-158262000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	153208000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	879874000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-39791000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	293249000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	173646000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	119603000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	102876000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	933431000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	166935000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	766496000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-29627000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	1003455000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	153398000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	850057000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	323038000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92382000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3393669000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118846000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2018Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	331618000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	6841960000	USD
CY2018Q4	dva	Current Liabilities Excluding Held For Sale CurrentLiabilitiesExcludingHeldForSale	3647402000	USD
CY2018Q4	us-gaap	Assets Assets	19110252000	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1243759000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4891161000	USD
CY2018Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2018Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9186052000	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1124641000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	3703442000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	204956000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3908398000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19110252000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	508234000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	10686000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1714750000	USD
CY2017Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	775389000	USD
CY2017Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5761642000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	8770701000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3149213000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	113827000	USD
CY2017Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2017Q4	us-gaap	Due From Related Parties Noncurrent DueFromRelatedPartiesNoncurrent	0	USD
CY2017Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	330516000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	6610279000	USD
CY2017Q4	us-gaap	Assets Assets	18974536000	USD
CY2017Q4	dva	Current Liabilities Excluding Held For Sale CurrentLiabilitiesExcludingHeldForSale	1882450000	USD
CY2017Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1185070000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3067520000	USD
CY2017Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	0	USD
CY2017Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	10009590000	USD
CY2017Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1011360000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	4690029000	USD
CY2017Q4	us-gaap	Minority Interest MinorityInterest	196037000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4886066000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18974536000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2018	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1438600000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1771640000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	987138000	USD
CY2018	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	183156000	USD
CY2018	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	150205000	USD
CY2018	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-14446000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1005643000	USD
CY2018	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	694777000	USD
CY2018	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1320131000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-625354000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-3350000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137293000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	518920000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	415420000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	830555000	USD
CY2017	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1082611000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1913166000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	905250000	USD
CY2017	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	803879000	USD
CY2017	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	92336000	USD
CY2017	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-252061000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1364732000	USD
CY2017	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	154848000	USD
CY2017	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-921105000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-766257000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	254000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-217569000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	683463000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	518920000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	1033082000	USD
CY2016	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	939044000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1972126000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	829095000	USD
CY2016	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	563856000	USD
CY2016	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	64725000	USD
CY2016	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-126558000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1201668000	USD
CY2016	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-124442000	USD
CY2016	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1227539000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1351981000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4276000	USD
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-577247000	USD
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1244917000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	683463000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	204956000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-39791000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	293249000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	173646000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	119603000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	323038000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	92382000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3908398000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1858608000	USD
CY2018Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	760566000	USD
CY2018Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5389565000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	8424159000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3393669000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118846000	USD
CY2018Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	331618000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	6841960000	USD
CY2018Q4	us-gaap	Assets Assets	19110252000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10709981000	USD
CY2018	us-gaap	Health Care Organization Patient Service Revenue Provisionfor Bad Debts HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts	49587000	USD
CY2018	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	10660394000	USD
CY2018	us-gaap	Other Income OtherIncome	744457000	USD
CY2018	us-gaap	Revenues Revenues	11404851000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	9879027000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	1525824000	USD
CY2018	us-gaap	Interest And Debt Expense InterestAndDebtExpense	487435000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10089000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	258400000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	790078000	USD
CY2018	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-457038000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	173646000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	159394000	USD
CY2018Q4	dva	Current Liabilities Excluding Held For Sale CurrentLiabilitiesExcludingHeldForSale	3647402000	USD
CY2018Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1243759000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4891161000	USD
CY2018Q4	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	0	USD
CY2018Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9186052000	USD
CY2018Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1124641000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	3703442000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19110252000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	333040000	USD
CY2018	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1438600000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1771640000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	987138000	USD
CY2018	us-gaap	Payments For Proceeds From Businesses And Interest In Affiliates PaymentsForProceedsFromBusinessesAndInterestInAffiliates	183156000	USD
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	150205000	USD
CY2018	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-14446000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1005643000	USD
CY2018	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	694777000	USD
CY2018	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	0	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1320131000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-625354000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-3350000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	137293000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	518920000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	415420000	USD

Files In Submission

Name	View Source	Status
0000927066-19-000025-index-headers.html	Edgar Link	pending
0000927066-19-000025-index.html	Edgar Link	pending
0000927066-19-000025.txt	Edgar Link	pending
0000927066-19-000025-xbrl.zip	Edgar Link	pending
centerbystateusmap21.jpg	Edgar Link	pending
chart-100a0357e0a359af83f.jpg	Edgar Link	pending
chart-1cc8058f87e956aca13.jpg	Edgar Link	pending
chart-30bc3207026e5c36a41.jpg	Edgar Link	pending
davitalogorgbfa07.jpg	Edgar Link	pending
dva-123118x10k.htm	Edgar Link	pending
dva-123118x10k_htm.xml	Edgar Link	completed
dva-123118xex1010.htm	Edgar Link	pending
dva-123118xex1013.htm	Edgar Link	pending
dva-123118xex1019.htm	Edgar Link	pending
dva-123118xex1032.htm	Edgar Link	pending
dva-123118xex211.htm	Edgar Link	pending
dva-123118xex23.htm	Edgar Link	pending
dva-123118xex231.htm	Edgar Link	pending
dva-123118xex311.htm	Edgar Link	pending
dva-123118xex312.htm	Edgar Link	pending
dva-123118xex321.htm	Edgar Link	pending
dva-123118xex322.htm	Edgar Link	pending
dva-20181231.xsd	Edgar Link	pending
dva-20181231_cal.xml	Edgar Link	unprocessable
dva-20181231_def.xml	Edgar Link	unprocessable
dva-20181231_lab.xml	Edgar Link	unprocessable
dva-20181231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2018 Q4 Form 10-K Financial Statement

#000092706619000025 Filed on February 22, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2018 Q4 Form 10-K Financial Statement

#000092706619000025 Filed on February 22, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva